Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus placebo plus SoC
ipilimumab plus SoC
CA184-156, 2016
  NCT01450761
RCTExtensive stage SCLC (Es-SCLC) - 1st Line (L1)Ipilimumab plus etoposide plus platinePlacebo plus etoposide plus platinephased induction schedule followed by maintenance in patients with Extensive-Stage Small-Cell Lung Cancer (no prior systemic therapy for ED-SCLC)566 / 566high
inconclusive
  • inconclusive 6 % decrease in deaths (OS) (PE)
  • suggested 15 % decrease in progression or deaths (PFS)